HOME >> BIOLOGY >> NEWS
Drug protects brain cells in Huntington's disease model, researchers find

ealth insurance. There are treatments to lessen the symptoms, but there is currently no way to slow or halt the progression of the disease.

In the current study, the UT Southwestern researchers used mice that were genetically engineered to carry the mutant human gene for Huntingtons, causing symptoms and death of brain cells similar to those seen in the disease. The study focused on an area of the brain called the striatum, which plays a critical role in relaying signals concerning motion and higher thought and receives signals from several brain regions.

The striatum is primarily made up of nerve cells called medium spiny neurons, which undergo widespread death in Huntingtons. One major input to the striatum comes from an area called the substantia nigra, which controls voluntary movements and sends signals to the striatum via nerve cells that release dopamine.

The researchers conducted various coordination tests on both normal and genetically manipulated mice. Engineered mice given a drug that increased brain dopamine levels performed worse on these tasks, while TBZ protected against this effect. Most importantly, TBZ appears to reduce significantly cell loss in the striatum of the engineered mice, the scientists report.

More research is needed to determine whether this protective effect might also be present in humans, and also whether at-risk people would benefit from the drug, Dr. Bezprozvanny said.

Clinical trials in humans would be very difficult, however, because trials require many participants and there is no easy way to score effectiveness of a presymptomatic drug, Dr. Bezprozvanny said. Thus, his future studies in animals will look at the effectiveness of TBZ given just after initial symptoms have developed. This situation simulates what would probably happen in a human trial, he said.


'"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
24-Jul-2007


Page: 1 2

Related biology news :

1. Reading ability protects brain from lead exposure
2. Research shows NPD1 protects a key component of vision
3. A gene that protects from kidney disease
4. PINK1 protects from Parkinsons
5. Enzyme delivered in smaller package protects cells from radiation damage
6. Parkinsons protein protects neurons from stress induced cell death
7. Caspase-14 protects our skin against UVB and dehydration
8. Reproductive speed protects large animals from being hunted to extinction
9. Molecule that destroys bone also protects it, new research shows
10. Peramivir protects mice from lethal H5N1 infection
11. Estrogen protects liver after traumatic injury

Post Your Comments:
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/27/2015)... 2015 ­ Caris Life Sciences®, a leading ... medicine, today announced it has appointed the Levine Cancer ... excellence site in the Caris Centers of Excellence for ... Institute is one of the largest cancer care providers ... cancer patients annually. Derek Raghavan , M.D., Ph.D., ...
(Date:5/26/2015)... 2015 Regenestem Network has ... clinic in Buenos Aires, Argentina. The clinic will be ... specialist. Pastrana has assembled a multidisciplinary team of medical ... her state-of-the-art Puerto Madero office. , The new ... phase IV clinical studies in cellular therapies, and establish ...
(Date:5/26/2015)... 26, 2015 Innovacyn, a leader ... the human and animal health industries, announced today ... Innovators of Agriculture College Scholarship Award. The scholarship ... exhibits a passionate commitment to the agriculture industry ... year’s winners, Alexis Pedrow from Anderson County Jr/Sr ...
(Date:5/26/2015)... and HILDEN, Germany ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... its QIAGEN Clinical Insight ® (QCI™) bioinformatics ... to interpret and report on genomic variants identified ... applications for the bioinformatics platform are in oncology, ...
Breaking Biology Technology:Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5
Cached News: